Literature DB >> 17592551

Survivin expression in tuberous sclerosis complex cells.

Stephana Carelli1, Elena Lesma, Simona Paratore, Vera Grande, Giorgia Zadra, Silvano Bosari, Anna Maria Di Giulio, Alfredo Gorio.   

Abstract

Tuberous Sclerosis Complex (TSC) is a tumor suppressor gene disorder with mutations of TSC1/TSC2 genes. This leads to the development of hamartomas that most frequently affect central nervous system, kidney, and skin. Angiomyolipomas are abdominal masses made up of muscle vessels and adipose tissues that grow mostly in proximity to kidneys and liver. Bleeding and kidney failure are the major justification for surgery. This study shows that angiomyolipoma-derived human smooth muscle TSC2-/- cells express the apoptosis inhibitor protein survivin when exposed to IGF-1. Survivin expression is also triggered whenever culture conditions perturb normal TSC2-/- cell function, such as the omission of EGF from the growth medium, the supplementation of anti-EGFR, blockade of PI3K and ERK, or inhibition of mTOR. Interestingly, single or simultaneous inhibition of PI3K by LY294002 and ERK by PD98059 does not prevent IGF-1-mediated survivin expression. Apoptogenic Smac/DIABLO, which is constitutively expressed by TSC2-/- A+ cells, is down-regulated by IGF-1 even in the presence of LY294002 and PD98059. These cells release IGF-1 by means of a negative feedback-regulated mechanism that is overrun when they are exposed to antibodies to IGF-1R, which increases the released amount by more than 400%. The autocrine release of IGF-1 may therefore be a powerful mechanism of survival of the tightly packed cells in the thick-walled vessels of TSC angiomyolipoma and in lymphangioleiomyomatosis (LAM) nodules. Future experimental therapies for TSC and LAM may result from the targeted inhibition of survivin, which may enhance sensitivity to TSC2 therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592551      PMCID: PMC1892757          DOI: 10.2119/2006–00091.Carelli

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  58 in total

1.  Control of apoptosis during angiogenesis by survivin expression in endothelial cells.

Authors:  D S O'Connor; J S Schechner; C Adida; M Mesri; A L Rothermel; F Li; A K Nath; J S Pober; D C Altieri
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement.

Authors:  M A Verdecia; H Huang; E Dutil; D A Kaiser; T Hunter; J P Noel
Journal:  Nat Struct Biol       Date:  2000-07

3.  Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth.

Authors:  J Chen; W Wu; S K Tahir; P E Kroeger; S H Rosenberg; L M Cowsert; F Bennett; S Krajewski; M Krajewska; K Welsh; J C Reed; S C Ng
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

4.  Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.

Authors:  M van Slegtenhorst; M Nellist; B Nagelkerken; J Cheadle; R Snell; A van den Ouweland; A Reuser; J Sampson; D Halley; P van der Sluijs
Journal:  Hum Mol Genet       Date:  1998-06       Impact factor: 6.150

5.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

Authors:  T Carsillo; A Astrinidis; E P Henske
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

6.  Anti-apoptosis gene, survivin, and prognosis of neuroblastoma.

Authors:  C Adida; D Berrebi; M Peuchmaur; M Reyes-Mugica; D C Altieri
Journal:  Lancet       Date:  1998-03-21       Impact factor: 79.321

7.  Prevalence of tuberous sclerosis estimated by capture-recapture analysis.

Authors:  F J O'Callaghan; A W Shiell; J P Osborne; C N Martyn
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

8.  Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting.

Authors:  G Ambrosini; C Adida; G Sirugo; D C Altieri
Journal:  J Biol Chem       Date:  1998-05-01       Impact factor: 5.157

9.  A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.

Authors:  R A Olie; A P Simões-Wüst; B Baumann; S H Leech; D Fabbro; R A Stahel; U Zangemeister-Wittke
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

10.  Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells.

Authors:  J Tran; J Rak; C Sheehan; S D Saibil; E LaCasse; R G Korneluk; R S Kerbel
Journal:  Biochem Biophys Res Commun       Date:  1999-11-02       Impact factor: 3.575

View more
  8 in total

1.  Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.

Authors:  Anya Alayev; Rachel S Salamon; Yang Sun; Naomi S Schwartz; Chenggang Li; Jane J Yu; Marina K Holz
Journal:  Am J Respir Cell Mol Biol       Date:  2015-11       Impact factor: 6.914

Review 2.  Lymphangioleiomyomatosis and TSC2-/- cells.

Authors:  Thomas N Darling; Gustavo Pacheco-Rodriguez; Alfredo Gorio; Elena Lesma; Cheryl Walker; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

Review 3.  Clinical and molecular insights into tuberous sclerosis complex renal disease.

Authors:  Brian J Siroky; Hong Yin; John J Bissler
Journal:  Pediatr Nephrol       Date:  2010-12-09       Impact factor: 3.714

4.  Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.

Authors:  Christopher W Chiu; Hiroaki Nozawa; Douglas Hanahan
Journal:  J Clin Oncol       Date:  2010-09-07       Impact factor: 44.544

5.  The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells.

Authors:  Elena Lesma; Silvia Maria Sirchia; Silvia Ancona; Stephana Carelli; Silvano Bosari; Filippo Ghelma; Emanuele Montanari; Anna Maria Di Giulio; Alfredo Gorio
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

6.  TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.

Authors:  Elena Lesma; Silvia Ancona; Silvia M Sirchia; Emanuela Orpianesi; Vera Grande; Patrizia Colapietro; Eloisa Chiaramonte; Anna Maria Di Giulio; Alfredo Gorio
Journal:  J Cell Mol Med       Date:  2014-03-07       Impact factor: 5.310

7.  Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis.

Authors:  Elena Lesma; Eloisa Chiaramonte; Silvia Ancona; Emanuela Orpianesi; Anna Maria Di Giulio; Alfredo Gorio
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

8.  Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM.

Authors:  Elena Lesma; Vera Grande; Silvia Ancona; Stephana Carelli; Anna Maria Di Giulio; Alfredo Gorio
Journal:  PLoS One       Date:  2008-10-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.